g-ba node boost outlook still search path
analyst day note focu outpac market growth
updat wagework
sci-b-vac succe protect lower pt
reduct sale pivot toward chronic wound
increment updat set stage
analyst certif import disclosur see
take long view blood-bas screen singular bolt-on
offer platform sustain growth
ind accept support potenti updat
program multipl myeloma
readout support acceler approv voxelotor
zynteglo price shot chase sooth efficaci data eha
durabl respons clean safeti point registr
opportun dlbcl outperform
favor updat eular reiter outperform
eha data support biomark strategi acceler
clinic valid revers btk news
noth sneez breathtak rsv result
highlight fda circulatori system review panel paclitaxel-co devic safeti panelist note clear
efficaci benefit devic suggest panel fda therapi remov panelist note
mortal signal present data shown ignor fda point question
strength data discuss yesterday panelist ask evalu mortal signal data
call data form remain open question label panelist suggest way fda could convey devic
benefit also ensur patient awar mortal signal seen overal appear current statu larg
remain near-termcontinu therapi avail suggest physicians/pati discuss benefits/risk given
patient situat industri alreadi reduc near-term estim follow fda march advisori letter
top stori week learn increas disagr administr hh hh secretari
battl top white hous aid number issu includ drug-pric medicaid fetal tissu
research prioriti addit also learn administr seema verma express disagr
number anti-aca polici although immin chang expect disagr could concern
healthcar investor hope stabl approach hh
g-ba node boost outlook still search path sustain growth
expect german feder joint committe g-ba issu posit opinion open reimburs
oncotyp dx breast germani public health servic node neg er breast cancer decis de-risk
ghdx ex-u growth outlook begin posit compani view mani investor may
search sustain path top-lin growth support multipl expans ghdx share
believ fundament shift product portfolio transit oncotyp dx breast oncotyp dx
ivd platform particularli eu may necessari push ghdx share current trade rang maintain
exit start prepar sales/earn season overwhelm theme meet
investor us ex-u whether large-cap biotech oversold see exhibit could sector outperform
posit note hint emerg biotech ralli due low sales/
earn expect continu strong smid-cap trend concord rhetor drug price fade
exhibit us presidenti elect politick begin earnest probabl meaning legisl
enact congress also decreas like set-up advis investor start dip feet back biotech
eye perform believ tee-up well snss clsn materi catalyst
approach also continu like arql catb fundament perspect
analyst day note focu outpac market growth updat wagework
hqi analyst day yesterday focus current market condit opportun strategi continu
outpac market growth hsa aum apart stress import expand product portfolio beyond
hsa less discuss wagework acknowledg decreas growth hsa interest
rate manag stress target grow market hsa aum believ polit rhetor
around healthcar keep stock volatil regulatori chang near term seem unlik despit market
headwind growth believ hsa attach healthcar best option engag consum help save
curtail healthcar cost inflat think best posit
day one fda circulatori system devic panel safeti paclitaxel-co peripher vascular devic
panelist note mortal signal paclitaxel data present vs control appear present conflict data lack
signific long-term data miss data point howev leav lack definit fda present suggest
higher rate mortal paclitaxel devic base analysi follow industri repres highlight data
show correl paclitaxel higher mortal studi panelist said data dont
definit point class effect also note enough data delin devic today day
panelist ask propos label chang post-market studi need comment current/
potenti indic paclitaxel overal risk/benefit devic among other day one highlight
ntec share under-perform vs nbi flat base pk studi result view
favor recent host kol event two world lead author parkinson diseas pd dr
warren olanow neurolog professor neurosci chairman emeritu mount sinai school medicin dr karl
kieburtz professor neurolog public health scienc univers rochest discuss import
continu dopaminerg stimul levadopa ld pd current approach aim deliv better pk/pd
profil ld includ ntec accordion pill ap dr olanow believ smoother ld pk/pd profil improv efficaci
safeti view ap-cd/ld studi rel derisk post pk data
yesterday announc cfo florin retir effect juli succeed suketu upadhyay florin
cfo zimmer biomet sinc june cfo biomet prior merger zimmer sinc overal
look smooth transit florin successor place florin expect continu advisori
capac extend period time help cfo transit assist sever on-going financi
oper initi florin upadhyay call upadhyay two decad experi
senior financi role healthcar recent svp global financi oper bristol-my squibb
updat model follow biohaven equiti rais maintain outperform thesi believ
stronger balanc sheet better posit launch rimegep assum approv updat price target
vs continu assum us rimegep launch without partner sale reach year
outright sale cgrp platform may like believ manag would act best interest
sharehold view upsid scenario factor target addit migrain platform
note sever valu driver may reflect current price remain cautious excit next
caught hsdt manag follow yesterday busi updat fda strategi resubmit de novo
applic pon portabl neuromodul stimul devic manag note compani held inform
discuss fda june regard issu rais april reject letterspecif around fda note
ascertain rel contribut physic therapi pt alon versu pon hsdt initi submiss hsdt
plan submit presubmiss letter fda month-end expect meet around mid-septemb order
final resubmiss protocol compani anticip requir data proactiv initi studi gener
pt alon data new studi util design studi includ five-week treatment period
inclusion/exclus requir expect start enrol patient end juli manag take
initi need step toward resubmiss look visibl final pathway fda suggest time
rate share perform key mileston includ anoth updat follow fda presubmiss meet potenti
approv europe/australia
sci-b-vac succe protect lower pt
achiev co-primari endpoint first two phase trial vs current standard care hepat vaccin
candid sci-b-vac develop remain track us/eu regulatori file start expect sci-b-vac
demonstr significantli higher seroprotect subgroup insuffici met current option well benign safeti
may blame secondari endpoint miss sharp stock price declin share heavi volum monday
knowledg promulg two-dos non-inferior three-dos soc view critic
regulatory/commerci prospect item re-analyz incorpor phase constant data
sci-b-vac engerix-b mind potenti near-term share dilut nonetheless see current ev
attract risk-toler investor
reduct sale pivot toward chronic wound reflect necessari skint cours correct
sinc june disclos three import revis commerci model includ replac ceo denver
lough offic chief execut simplifi skint price structur cut price chronic
wound reduc headcount defer certain capit expenditur control expens furthermor
recent convers manag observ mark chang tone toward busi develop view
signific corpor collabor unlik net believ chang posit long-term success
skint chronic wound base competit price narrow commerci focu
announc drug enforc agenc design sunosi solriamfetol schedul iv medicin recal
fda approv sunosi tablet improv wake adult patient excess daytim sleepi associ
narcolepsi obstruct sleep apnea osa view schedul iv design posit sunosi favor
competit market model us revenu grow time maintain
outperform rate price target continu view sleep franchis profit busi allow
manag pursu near-term capit deploy opportun sunosi commerci avail earli juli
manag expect provid addit launch detail time
increment updat set stage
attend annual european hematolog associ eha meet june amsterdam
netherland updat revers btk inhibitor take focu univers believ setup
decemb could impact particularli snss vecabrutinib among addit updat across hematolog
malign blood disord landscap eha popular perspect grow clinician demand
leverag closer front-lin set addit popul subset price debat focu
cell product manufactur remain near-term focu technolog increment bullish long-term
market potenti product highlight key takeaway
share ralli vs nbi flat posit studi result treatment vitiligo
topic ruxolitinib view opportun potenti import fda approv therapi
vitiligo autoimmun diseas seriou medic outcom go beyond physic appear four dose regimen
topic ruxolitinib compar vehicl cream primari endpoint week topic ruxolitinib show
statist signific superior placebo dose regimen importantli
stringent endpoint score improv demonstr strong dose respons increas longer treatment durat
dose topic ruxolitinib well toler side effect profil similar placebo detail insid
product enhanc check enclos proprietari work ky rfp passport financi
fl medicaid enrol competit check pace enrol latest medicar hear
rhetor substanc per khn hospit focus revenue growth cost cut amid improv
margin per abco ceo survey mhn final press ganey acquir
leonard green partner close expect term disclos week hold analyst day
wed full calendar page
take long view blood-bas screen singular bolt-on offer platform sustain growth
busi model built larg measur innov method use technolog lower cog
maintain high qualiti data announc acquisit singular roughli million share
close view transact long-term call option shift blood-bas screen potenti lower cost singl
molecul microarray-bas approach nip first applic view platform may applic blood-
base liquid biopsi import specif takeaway transact includ synergist nip product
potenti lower cog could offer differenti expand market among low risk pregnanc new nip
optim month cash neutral reiter outperform
ind accept support potenti updat program multipl myeloma
fda accept ind compound incorpor etb shiga toxin-bas platform
promot intern expect ind time support enrol multipl cohort dose escal
end complet expans cohort relapsed/refractori multipl myeloma patient middl
phase studi design post clinicaltri gov yet whether dose escal data
present earli decemb depend robust clinic respons initi dose cohort view
given increasingli crowd landscap compound believ partner takeda may wait present
matur data eha
readout support acceler approv voxelotor
friday result pivot studi evalu voxelotor sickl cell anemia sca present well-attend
symposium eha concomit public nejm consist interim data easili hit primari endpoint
hemoglobin hb respons clean safeti profil given evid link chronic hemolyt anemia organ damag
sca fda allow hb respons hope primari endpoint view investor remain sidelin due
linger uncertainti voxelotor potenti deliv long-term benefit worri design confirmatori trial
lose sight bigger pictur physician would eagerli prescrib drug voxelotor properti global blood
track complet nda submiss reiter outperform pt
zynteglo price shot chase sooth efficaci data eha
bio put strong show eha confer amsterdam deliv increment posit updat gene
therapi program sickl cell anemia sca transfusion-depend -thalassemia tdt multipl oral present
updat group trial sca particularli impress highli symptomat transfusion-
depend patient display dramat improv blood qualiti reduc diseas symptom suggest
treatment work intend confer bluebird announc propos price zynteglo divid
five yearli instal condit sustain benefit see zynteglo value-bas reimburs strategi
necessari uptak anticip extrem slow launch ramp first commerci patient may treat
durabl respons clean safeti point registr opportun dlbcl outperform
saturday new data phase trial rituximab nhl present eha combin
activ heavili pretreat patient respons rate may cutoff declin publish eha abstract
valueslik reflect inclus addit elderli patient phase expans cohort given combin
overal efficaci r/r dlbcl rel mild safeti profil fda guid recent type
 meet approv car-t inelig patient could support single-arm pivot trial believ initi
approv car-t inelig popul could lower barrier label expans larger segment dlbcl market
favor updat eular reiter outperform
increment data lenabasum matur phase open-label extens studi system sclerosi month
dermatomyos month present eular continu distinguish agonist set highlight
import long-term treatment potenti orphan disord chronic lack cur option
lenabasum demonstr durabl effect well safeti posit attract therapeut option phase
readout lie time away top-lin ssc next summer dm optimist success
indic also remind investor potentially-pivot phase data cf also posit bias
eha data support biomark strategi acceler registr pathway
present data expans cohort studi tipifarnib relapsed/refractori
weekend eha provid busi updat data r/rptcl unselect cohort aitl cohort
present eha updat incud addit aitl snp expans cohort
data cohort tipifarnib bid administ day treatment cycl tipifarnib activ
primari endpoint orr high express aitl ptcl-no tumor orr snp
aitl aitl subgroup increas activ orr assess
regulatori pathway may adcetris-lik single-arm studi later line
clinic valid revers btk news
friday non-coval btk inhibitor arq made splash eha impress data phase trial multipl
respons demonstr cll patient mutat common mechan resist coval
btk inhibitor like ibrutinib believ data de-risk develop non-coval btk inhibitor includ
aptos current screen patient b-cell malign inclus first-in-human trial believ
trial mg start dose could show clinic activ help aptos narrow gap competitor separ
compani present updat preclin data show potenc mutant aml recent complet financ
may extend compani cash runway key clinic readout expect reiter outperform pt
noth sneez breathtak rsv result
announc posit top-line result human challeng studi healthi volunt provid proof
concept novel potent non-fus inhibitor respiratori syncyti viru rsv reduc rsv viral load
clinic symptom highli statist signific result compar placebo forecast un-risk adjust
peak sale base us patient treat assign probabl success
base publish probabl success infecti diseas drug add rsv
model remov pbc base slow enrol maintain pt look forward
public full challeng studi data detail insid
held annual investor day friday compani mani busi line appear perform well
includ stabl exchang busi furthermor manag remain optimist around strategi acquir wellcar
approv process on-track look forward provid visibl revenu
driven growth medicare/medicaid hif off-set reduc pass-through compani also provid pro forma
revenues/ebitda post-wcg compar lastli continu boast
impress technologically-driven invest portfolio build acquisit rxadvanc addit behavior
platform quartet given centen strong posit attract valuat maintain outperform rate would
continu buyer
june spark institut biotech summit stanford univers menlo park ca
healthcar provid manag
